Bio-Rad Laboratories shares surge 16.13% intraday after reporting strong Q2 2025 earnings, driven by life science and food safety product sales.

Bio-Rad Laboratories, Inc. surged 16.13% intraday, following the release of its second-quarter 2025 financial results, which showed a 2.1% year-over-year increase in total net sales to $651.6 million, driven primarily by growth in the life science segment and process chromatography and food safety products.